Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema

scientific article published on 01 February 2006

Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JACI.2005.10.045
P698PubMed publication ID16461161

P50authorTeresa CaballeroQ52822293
P2093author name stringConcepción López-Serrano
P433issue2
P921main subjecthereditary angioedemaQ2096745
anaphylaxisQ168800
P304page(s)476-7; discussion 477
P577publication date2006-02-01
P1433published inThe Journal of Allergy and Clinical ImmunologyQ7743550
P1476titleAnaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema
P478volume117

Reverse relations

cites work (P2860)
Q36839961C1-inhibitor deficiencies (hereditary angioedema): where are we with therapies?
Q37354117Current and emerging management options for hereditary angioedema in the US.
Q38021414Current management options for hereditary angioedema
Q36373700Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project
Q34575895Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant
Q34067727HAE international home therapy consensus document.
Q34063768HAE therapies: past present and future
Q34741437Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies
Q36998879Human plasma kallikrein-kinin system: physiological and biochemical parameters
Q34139106Management of acute attacks of hereditary angioedema: potential role of icatibant
Q35623619Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.